VYGR
$3.79
Voyager Therapeut
($.12)
(3.07%)
VYGR
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.75)
Revenue:  $3.29 Mil
Monday
Nov 8
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VYGR reports earnings?
Beat
Meet
Miss

Where is VYGR's stock price going from here?
Up
Flat
Down
Stock chart of VYGR
Analysts
Summary of analysts' recommendations for VYGR
Score
Grade
Pivots
Resistance
$4.08
$3.99
$3.89

$3.79

Support
$3.70
$3.60
$3.50
Tweet
Growth
Description
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.